Background/Aims: Sinonasal mucosal melanoma (SMM) is a rare but extremely aggressive disease. Interestingly, however, as lethal as SMM, a few patients could survive for over 5 years without metastasis. However, biomarkers for metastatic SMM are lacking. Methods: Laser-capture microdissection combined with microRNA microarray and RT-qPCR was performed in formalin-fixed paraffin-embedded tissue samples from SMM patients whose follow-up studies were carried out in parallel. In vitro cell proliferation and invasion assays, gelatin zymography, western blot analysis and RT-qPCR were performed in melanoma cell lines. Results: In the discovery stage, miR-4633-5p expressed differentially in sinonasal mucosal melanoma patients with short and long dis...
BACKGROUND:Mitogen activated-protein kinase pathway inhibitors (MAPKis) improve treatment outcome in...
In metastatic melanoma, it is vital to identify and validate biomarkers of prognosis. Previous studi...
miR-193a: potential therapeutic agent and biomarker in cutaneous melanoma Background. MicroRNAs ...
Malignant cutaneous melanoma is a highly aggressive form of skin cancer. Despite improvements in ear...
peer reviewedThe non-coding microRNAs (miRNA) have tissue- and disease-specific expression patterns....
We previously identified miR-4731-5p (miR-4731) as a melanoma-enriched microRNA following comparison...
Although deregulated expression of microRNAs (miRNAs) demonstrably contributes to the development an...
Melanoma is a devastating disease with few therapeutic options in the advanced stage and with the ur...
Cutaneous melanoma is an aggressive neoplasm and is responsible for the majority of skin cancer deat...
peer reviewedMiRNAs are increasingly recognized as biomarkers for the diagnosis of cancers where the...
MicroRNAs are small noncoding RNAs that regulate gene expression and have important roles in various...
Melanoma is an aggressive cancer that metastasizes rapidly and is refractory to conventional chemoth...
Background: Melanoma is the fourth and sixth most common malignancy in men and women, respectively, ...
Melanoma is the fourth and sixth most common malignancy in men and women, respectively, and the 5-ye...
According to the latest estimates, cancer is becoming an increasing health risk on a global scale. C...
BACKGROUND:Mitogen activated-protein kinase pathway inhibitors (MAPKis) improve treatment outcome in...
In metastatic melanoma, it is vital to identify and validate biomarkers of prognosis. Previous studi...
miR-193a: potential therapeutic agent and biomarker in cutaneous melanoma Background. MicroRNAs ...
Malignant cutaneous melanoma is a highly aggressive form of skin cancer. Despite improvements in ear...
peer reviewedThe non-coding microRNAs (miRNA) have tissue- and disease-specific expression patterns....
We previously identified miR-4731-5p (miR-4731) as a melanoma-enriched microRNA following comparison...
Although deregulated expression of microRNAs (miRNAs) demonstrably contributes to the development an...
Melanoma is a devastating disease with few therapeutic options in the advanced stage and with the ur...
Cutaneous melanoma is an aggressive neoplasm and is responsible for the majority of skin cancer deat...
peer reviewedMiRNAs are increasingly recognized as biomarkers for the diagnosis of cancers where the...
MicroRNAs are small noncoding RNAs that regulate gene expression and have important roles in various...
Melanoma is an aggressive cancer that metastasizes rapidly and is refractory to conventional chemoth...
Background: Melanoma is the fourth and sixth most common malignancy in men and women, respectively, ...
Melanoma is the fourth and sixth most common malignancy in men and women, respectively, and the 5-ye...
According to the latest estimates, cancer is becoming an increasing health risk on a global scale. C...
BACKGROUND:Mitogen activated-protein kinase pathway inhibitors (MAPKis) improve treatment outcome in...
In metastatic melanoma, it is vital to identify and validate biomarkers of prognosis. Previous studi...
miR-193a: potential therapeutic agent and biomarker in cutaneous melanoma Background. MicroRNAs ...